Total medical devices industry M&A deals worth $3.86bn were announced globally in March 2021, led by Boston Scientific’s $1.07bn asset transaction with Lumenis, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 39.4% over the previous month of $2.77bn and a drop of 49.3% when compared with the last 12-month average, which stood at $7.61bn.
Comparing M&A deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $2.41bn. At the country level, the US topped the list in terms of deal value at $2.23bn.
In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe top country in terms of M&A deals activity in March 2021 was the US with 23 deals, followed by the Germany with four and Canada with three.
In 2021, as of March, medical devices M&A deals worth $30.7bn were announced globally, marking an increase of 1029.1% year on year.
medical devices industry M&A deals in March 2021: Top deals
The top five M&A deals accounted for 72.5% of the overall value during March 2021.
The combined value of the top five medical devices M&A deals stood at $2.8bn, against the overall value of $3.86bn recorded for the month.
The top five medical devices industry M&A deals of March 2021 tracked by GlobalData were:
1) Boston Scientific’s $1.07bn asset transaction with Lumenis
2) The $695m acquisition of Resolution Bioscience by Agilent Technologies
3) Agiliti’s $475m acquisition of Northfield Medical
4) The $320m acquisition of Asuragen by Bio Techne
5) Organon &’s acquisition of Alydia Health for $240m.
